Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zealand Pharma slips on Lantus combination delay

This article was originally published in Scrip

Executive Summary

Zealand Pharma's share price has slipped by DKK3 a share (4%) to DKK67 a share in early trading on 28 July in response to news that partner Sanofi is to begin Phase III trials in early-2013 with a Lantus combination product – around 12 months later than expected. The share price movement wiped DKK68.6 million ($13.45 million) off the company's value.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts